Non-cross resistant sequential single agent chemotherapy in first-line advanced non-small cell lung cancer patients: Results of a phase II study

Journal of Oncology

Volumn , Issue , 2009, Pages

  Surmont, V ^a   Aerts, J G J V ^a,b   Tan, K Y ^c   Schramel, F ^d   Vernhout, R ^a   Hoogsteden, H C ^a   Van Klaveren, R J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

^c SINT FRANCISCUS GASTHUIS   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 73549093613     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2009/457418     Document Type: Article

References (32)

1. Scagliotti G. V., Parikh P., von Pawel J., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer Journal of Clinical Oncology 2008 26 21 3543 3551
2. Fisher M. D., DOrazio A., Phase II and III trials: comparison of four chemotherapy regimens in advanced non-small cell lung cancer (ECOG 1594) Clinical Lung Cancer 2000 2 1 21 22
3. Fossella F., Pereira J. R., von Pawel J., Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group Journal of Clinical Oncology 2003 21 16 3016 3024
4. Le Chevalier T., Brisgand D., Douillard J.-Y., Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients Journal of Clinical Oncology 1994 12 2 360 367
5. Schiller J. H., Harrington D., Belani C. P., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer The New England Journal of Medicine 2002 346 2 92 98
6. Day R. S., Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy Cancer Research 1986 46 8 3876 3885
7. Norton L., Evolving concepts in the systemic drug therapy of breast cancer Seminars in Oncology 1997 24 4, supplement 10 S10 S3
8. Therasse P., Arbuck S. G., Eisenhauer E. A., New guidelines to evaluate the response to treatment in solid tumors Journal of the National Cancer Institute 2000 92 3 205 216 (Pubitemid 30099779)
9. Gebbia V., Galetta D., Caruso M., Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale Lung Cancer 2003 39 2 179 189
10. Edelman M. J., Clark J. I., Chansky K., Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel Clinical Cancer Research 2004 10 15 5022 5026
11. Clark J. I., Kancharla K., Qamar R., Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer Lung Cancer 2001 34 2 271 277
12. Grossi F., Belvedere O., Fasola G., Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an alpe-adria thoracic oncology multidisciplinary group study (ATOM 001) Lung Cancer 2004 46 1 99 106
13. Kubota K., Kawahara M., Ogawara M. O., Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study The Lancet Oncology 2008 9 12 1135 1142
14. Feliu J., Martin G., Lizon J., Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study Annals of Oncology 2001 12 10 1369 1374
15. Rixe O., Gatineau M., Jauffret E., Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Bulletin du Cancer 2005 92 1 E1 E6
16. Manegold C., Tatcher N., Kortsik C., Sequencing of single-agent (SA) docetaxel (T) and gemcitabine (G) therapy for patients (pts) with advanced non-small cell lung cancer (NSCLC): results of three consecutive randomized trials Journal of Clinical Oncology 2006 24 18s 7035
17. Martoni A. A., di Fabio F., Melotti B., Giaquinta S., Guaraldi M., Planned sequence of gemcitabine followed by vinorelbine in the treatment of elderly patients with advanced non-small cell lung cancer Anticancer Research 2006 26 2B 1501 1505
18. Poon D., Foo K. F., Chew L., Leong S. S., Wee J., Tan E. H., Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer Annals of the Academy of Medicine Singapore 2006 35 1 33 37
19. Hirsh V., Latreille J., Kreisman H., Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbiditiesa multicenter phase II trial Lung Cancer 2005 49 1 117 123
20. Tibaldi C., Vasile E., Antonuzzo A., First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study British Journal of Cancer 2008 98 3 558 563
21. Vansteenkiste J., Vandebroek J., Dooms C., Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine Lung Cancer 2003 40 2 191 199
22. Lowe S. W., Ruley H. E., Jacks T., Housman D. E., P53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 1993 74 6 957 967
23. Akerley W., Glantz M., Choy H., Phase I trial of weekly paclitaxel in advanced NSCLC Journal of Clinical Oncology 1998 16 1 153 158
24. Akerley W., Paclitaxel in advanced NSCLC Chest 2000 117 1525 1555
25. Akerley W., Herndon J., Egorin M. J., CALBG 9731: phase II trial of weekly paclitaxel for advanced NSCLC Proceedings of the American Society for Clinical Oncology 1999 18 462a
26. DAddario G., Pintilie M., Leighl N. B., Feld R., Cerny T., Shepherd F. A., Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature Journal of Clinical Oncology 2005 23 13 2926 2936
27. Sederholm C., Hillerdal G., Lamberg K., Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group Journal of Clinical Oncology 2005 23 33 8380 8388
28. Belani C. P., Brodowicz T., Ciuleanu T., Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology 2009 27 18s
29. Fidias P. M., Dakhil S. R., Lyss A. P., Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced NSCLC Journal of Clinical Oncology 2009 27 4 591 598
30. Olaussen K. A., Dunant A., Fouret P., DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy The New England Journal of Medicine 2006 355 10 983 991
31. Cobo M., Isla D., Masuti B., Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer Journal of Clinical Oncology 2007 25 19 2747 2754
32. Simon G., Sharma A., Li X., Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced NSCLC Journal of Clinical Oncology 2007 25 19 2741 2746